Wednesday, May 08, 2024 The Phase III Team Award for CCTG-Led Trials was presented to the PR21 team from the BC Cancer at the Annual Spring Meeting this past weekend. The team members include, Kim Chi (QI), Jeffrey Cheng, Sukhpreet Sidhu, Je Lee, Vivian Chew, Ming Chang, Natassja Eigl, Karen Stearman, Lyn Lorenzen, Kitty Sit, Maria Abaca, Kathy Ng, Jennifer Hoang, Kailey Dodd, Veronika Beiler, June Clark, Kelly Halvorsen, Loveneet Boyal, Lauren Hull, Sarah Farnalls, Julita Sienkiewicz, Haerim Roncin, Hershel Flores, Clarissa Kennedy, Stephanie Lo, Rio Aguilar, Kalina Kojwang, Amanda De Ruiter, Tina Alden, Erin Postlethwaite, Netalia Sandhu, Heather Saprunoff, Karen Arnason, Margaret Kliman-Depa, Corinna Warbuton, Wendy Won, Rongrong Karim, Lina Hashimoto, Thomas Htan, Mandeep Bains, David Hui.“We are so pleased to have received the team award for our efforts on PR21. It was a massive and monumental team effort to enroll this number of patients in such a relatively short time period on such a complex trial. We were motivated by our patients who were enthusiastic to participate, the important questions this trial will address and our responsibility to see that through in a timely manner.“ The CCTG PR21 is a randomized phase II study of 177Lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease. 177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study was to find out whether 177Lu-PSMA-617 can slow the growth of prostate cancer compared to standard chemotherapy treatment.
